PapersFlow Research Brief
Retinal Diseases and Treatments
Research Guide
What is Retinal Diseases and Treatments?
Retinal diseases and treatments encompass conditions affecting the retina such as diabetic retinopathy, age-related macular degeneration, and glaucoma, along with therapeutic interventions including intensive diabetes management, anti-VEGF agents, and emerging gene therapies.
Research on retinal diseases and treatments includes 100,875 works addressing complications like diabetic retinopathy, age-related macular degeneration, and glaucoma. Nathan et al. (1993) demonstrated that intensive therapy delays the onset and slows progression of diabetic retinopathy in insulin-dependent diabetes mellitus patients. Autophagy dysfunction contributes to ocular diseases, as shown by Li et al. (2015), while anti-VEGF therapies like ranibizumab improve visual acuity in neovascular age-related macular degeneration, per Rosenfeld et al. (2006).
Research Sub-Topics
Diabetic Retinopathy Progression
This sub-topic investigates pathophysiological mechanisms and risk factors for diabetic retinopathy development in insulin-dependent diabetes. Researchers study intensive glycemic control impacts on microvascular complications.
Age-Related Macular Degeneration Epidemiology
This sub-topic analyzes global prevalence, projections, and risk factors for AMD through systematic reviews. Researchers model disease burden and genetic-environmental interactions.
Anti-VEGF Therapy Neovascular AMD
This sub-topic evaluates ranibizumab and other anti-VEGF agents for wet AMD treatment outcomes. Researchers conduct clinical trials on injection protocols and long-term efficacy.
Glaucoma Global Prevalence
This sub-topic estimates worldwide glaucoma incidence and projections using meta-analyses. Researchers assess regional variations and screening needs.
Autophagy in Ocular Diseases
This sub-topic explores autophagy pathways in retinal degeneration and protection mechanisms. Researchers link dysregulation to AMD, retinopathy, and therapeutic modulation.
Why It Matters
Retinal diseases cause significant vision loss worldwide, with glaucoma as the second leading cause of blindness, disproportionately affecting women and Asians (Quigley, 2006), and age-related macular degeneration projected to increase in prevalence through 2040 (Wong et al., 2014). Intensive diabetes treatment reduces long-term complications including diabetic retinopathy, as evidenced by the Diabetes Control and Complications Trial involving 1441 patients over 6.5 years (Nathan et al., 1993). Anti-VEGF injections such as ranibizumab prevent vision loss in 95% of patients with neovascular age-related macular degeneration over 2 years (Rosenfeld et al., 2006). Deep learning algorithms detect referable diabetic retinopathy with high sensitivity and specificity in retinal fundus photographs (Gulshan et al., 2016). Recent developments include FDA approval of ENCELTO, the first cell-based therapy for MacTel, and Breakthrough Therapy Designation for Tinlarebant in Stargardt disease (Belite Bio, 2025). These treatments impact ophthalmology by preserving vision in millions affected by degenerative retinal conditions.
Reading Guide
Where to Start
"The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus" by David M. Nathan (1993) is the top-cited paper and provides foundational evidence on how glycemic control impacts diabetic retinopathy, making it essential for understanding treatment basics.
Key Papers Explained
Nathan et al. (1993) establish intensive diabetes therapy's role in delaying diabetic retinopathy. Ferrara et al. (2003) detail VEGF biology, foundational for anti-VEGF drugs like ranibizumab, validated by Rosenfeld et al. (2006) in improving acuity for age-related macular degeneration. Li et al. (2015) link autophagy dysfunction to ocular pathogenesis, extended by De Cillà et al. (2017) showing anti-VEGF modulation of autophagy and nitric oxide. Gulshan et al. (2016) apply deep learning to retinopathy detection, building on clinical needs from Nathan and Lang et al. (1974).
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints highlight gene therapy for posterior segment diseases including retinitis pigmentosa and inherited retinal dystrophies, with surgical updates on subretinal and suprachoroidal delivery ("Surgical Approaches to Retinal Gene Therapy: 2025 Update"). Nanoscope Therapeutics advances optogenetic therapy post-RESTORE Phase 2b trial (2025), while Belite Bio's Tinlarebant gains FDA Breakthrough Designation for Stargardt disease. ENCELTO becomes the first FDA-approved cell therapy for MacTel based on Phase 3 results.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | The Effect of Intensive Treatment of Diabetes on the Developme... | 1993 | New England Journal of... | 24.5K | ✓ |
| 2 | Repertoires of Autophagy in the Pathogenesis of Ocular Diseases | 2015 | Cellular Physiology an... | 16.3K | ✓ |
| 3 | The biology of VEGF and its receptors | 2003 | Nature Medicine | 9.5K | ✕ |
| 4 | The number of people with glaucoma worldwide in 2010 and 2020 | 2006 | British Journal of Oph... | 7.3K | ✓ |
| 5 | Development and Validation of a Deep Learning Algorithm for De... | 2016 | JAMA | 7.0K | ✕ |
| 6 | Global Prevalence of Glaucoma and Projections of Glaucoma Burd... | 2014 | Ophthalmology | 6.6K | ✕ |
| 7 | Ranibizumab for Neovascular Age-Related Macular Degeneration | 2006 | New England Journal of... | 5.8K | ✓ |
| 8 | Diabetic Retinopathy | 1974 | — | 5.6K | ✕ |
| 9 | Anti-Vascular Endothelial Growth Factors Protect Retinal Pigme... | 2017 | Cellular Physiology an... | 5.1K | ✓ |
| 10 | Global prevalence of age-related macular degeneration and dise... | 2014 | The Lancet Global Health | 5.0K | ✓ |
In the News
ExSight Ventures Invests in RevOpsis Therapeutics to ...
pioneering next-generation therapies for retinal diseases.
Nanoscope Therapeutics Initiates Rolling Submission ...
Nanoscope Therapeutics is developing gene-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTO...
Belite Bio Announces FDA Granting of Breakthrough Therapy ...
significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease...
Tiny eye implant becomes the first FDA-approved therapy for rare blindness
## Phase 3 trial results from Scripps Research and collaborators helped support FDA approval of ENCELTO, the first cell-based therapy for a neurodegenerative retinal condition called MacTel.
PolyActiva and RareSight partner to develop treatments for ...
- PolyActiva's phase 2b trial for PA5108 ocular implant targets glaucoma, supported by AUD $40 million in Series C funding.
Code & Tools
This repository contains a PyTorch-based deep learning model for classifying ocular diseases from retinal fundus images. The model leverages a cust...
The open-source software AUCMEDI allows fast setup of medical image classification pipelines with state-of-the-art methods via an intuitive, high-l...
A powerful Python package for importing, analyzing, and visualizing retinal imaging data, including OCT and OCT Angiography. header_gif
## Repository files navigation # Leveraging Multimodal Fusion for Enhanced Diagnosis of Multiple Retinal Diseases in Ultra-wide OCTA Official Pyt...
👀DeepSeeNet is a deep learning framework for classifying patient-based age-related macular degeneration severity in retinal color fundus photograp...
Recent Preprints
Advances in the treatment of blinding retinal diseases
Blinding retinal diseases, including inherited and degenerative conditions, rank globally among the primary causes of permanent vision loss. While certain degenerative retinal diseases like age-rel...
Can Gene Therapy Transform the Treatment Landscape of Posterior Segment Eye Diseases? A Comprehensive Review of Recent Advancements
Posterior segment eye diseases (PSEDs) encompass a diverse group of conditions affecting the retina, choroid, optic nerve, and vitreous humor, often leading to progressive and irreversible vision l...
Recent advances in treating age-related macular degeneration and diabetic retinopathy: Current therapies and emerging novel approaches
The present review article covers the pathogenesis of nAMD and PDR, focusing on the molecular aspects, provides a summary of the therapies currently used in standard medical practice, and discusses...
Surgical Approaches to Retinal Gene Therapy: 2025 Update
Gene therapy offers a promising new frontier in the treatment of inherited and acquired retinal disease. This review describes the current surgical delivery approaches for gene therapy to the retin...
Gene augmentation therapy restores vision and preserves photoreceptors in a mouse model of CNGA1 -retinitis pigmentosa
*Communications Medicine* **volume5**, Article number:384(2025) Cite this article * 3499Accesses * Metricsdetails ### Subjects * Gene therapy * Retinal diseases ## Abstract ### Background
Latest Developments
Recent developments in retinal diseases and treatments include the approval of the EYLEA HD® (aflibercept) injection for serious retinal conditions (Regeneron, 2026), advancements in retinal prosthetics that restore partial vision in patients (Powers Health, 2025), and ongoing gene therapy trials targeting inherited retinal diseases such as retinitis pigmentosa and RPE65-related dystrophy (Nature, 2024, Nature, 2025). Additionally, innovative tools are being developed to treat advanced retinal degenerations, aiming to improve outcomes even at later disease stages (ScienceDaily, 2025).
Sources
Frequently Asked Questions
What is the effect of intensive diabetes treatment on diabetic retinopathy?
Intensive therapy delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy in patients with insulin-dependent diabetes mellitus. This was shown in a trial with 1441 patients followed for a mean of 6.5 years (Nathan et al., 1993). The risk of retinopathy progression was reduced by 47-76% compared to conventional therapy.
How does autophagy relate to ocular diseases?
Autophagy is an intracellular process that degrades cytoplasmic proteins via lysosomes, and its dysfunction is implicated in ocular diseases. Autophagy-related proteins are constitutively expressed in ocular tissues (Li et al., 2015). It plays roles in pathogenesis of conditions like age-related macular degeneration and diabetic retinopathy.
What are the outcomes of ranibizumab for age-related macular degeneration?
Intravitreal ranibizumab prevents vision loss and improves mean visual acuity in patients with neovascular age-related macular degeneration. In a 2-year study, low rates of serious adverse events occurred (Rosenfeld et al., 2006). It targets choroidal neovascularization effectively.
How accurate is deep learning for detecting diabetic retinopathy?
A deep learning algorithm detects referable diabetic retinopathy in retinal fundus photographs with high sensitivity and specificity. It was validated on images from adults with diabetes (Gulshan et al., 2016). Clinical application requires further feasibility studies.
What is the global burden of glaucoma?
Glaucoma affected 60.5 million people worldwide in 2020, up from 39.5 million in 2010, making it the second leading cause of blindness. It disproportionately impacts women and Asians (Quigley, 2006; Tham et al., 2014). Projections estimate further increases through 2040.
What role do anti-VEGF agents play in protecting retinal cells?
Anti-VEGF agents like aflibercept and ranibizumab protect retinal pigment epithelium cells against oxidation by modulating nitric oxide release and autophagy. They reduce apoptosis and improve mitochondrial function in human retinal cells (De Cillà et al., 2017). This supports their use in macular degeneration treatment.
Open Research Questions
- ? How can gene therapy delivery methods such as subretinal, suprachoroidal, and intravitreal approaches be optimized for inherited retinal diseases?
- ? What are the long-term effects of optogenetic therapies like those from Nanoscope Therapeutics in patients blinded by retinal degeneration?
- ? How do novel VEGF/VEGFR signaling inhibitors compare to current anti-VEGF injections in treating neovascular age-related macular degeneration and proliferative diabetic retinopathy?
- ? Can autophagy modulation combined with anti-VEGF therapy further slow progression in oxidative stress-related retinal diseases?
- ? What multimodal imaging and AI models best predict treatment responses in diverse retinal conditions like diabetic retinopathy and glaucoma?
Recent Trends
Gene therapy emerges prominently, with preprints on augmentation restoring vision in CNGA1-retinitis pigmentosa mouse models and surgical delivery updates (2025).
2025Nanoscope Therapeutics initiated rolling submission for optogenetic therapy after RESTORE Phase 2b , targeting retinitis pigmentosa.
2025-07-14FDA granted Breakthrough Therapy Designation to Tinlarebant for Stargardt disease (Belite Bio, 2025-05-21) and approved ENCELTO cell therapy for MacTel.
2025-09-02Investments like ExSight Ventures in RevOpsis Therapeutics and PolyActiva's Phase 2b glaucoma implant (2025-11-07) signal focus on novel delivery for retinal diseases.
2025-09-16Research Retinal Diseases and Treatments with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Retinal Diseases and Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.